Novel Strategy for Synchronous Multiple Primary Lung Cancer Displaying Unique Molecular Profiles.

We report a rare case of multiple primary lung tumors displaying heterogeneous EGFR and KRAS molecular profiles, in which the patient underwent surgical resection of the gefitinib-insensitive peripheral lesion and continued gefitinib treatment for the gefitinib-sensitive bilateral multiple ground-glass opacity (GGO) lesions. The patient achieved complete remission and has been free of disease for 1.5 years. To the best of our knowledge, this novel strategy has not been previously reported. We consider our strategy to be safe and effective, and it appears to be a promising therapeutic approach for synchronous multiple primary lung cancer (SMPLC).